What compounds target RPS6KA4?

BiohacksAI has identified 33 compounds that interact with RPS6KA4 (Ribosomal protein S6 kinase alpha-4). Top compounds include: gefitinib, erlotinib, alvocidib, ruxolitinib, bi 2536. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is RPS6KA4 (Ribosomal protein S6)?

RPS6KA4 is Ribosomal protein S6 kinase alpha-4. It is a molecular target for 33 compounds documented in PubMed bioassay data.

RPS6KA4

MOLECULAR TARGET

Ribosomal protein S6 kinase alpha-4

33 compounds

RPS6KA4 (Ribosomal protein S6 kinase alpha-4) is targeted by 33 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting RPS6KA4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	erlotinib	5.55	256
3	alvocidib	4.52	91
4	ruxolitinib	4.23	68
5	bi 2536	4.01	54
6	midostaurin	3.85	46
7	nintedanib	3.61	36
8	tae 684	3.43	30
9	fedratinib	3.40	29
10	linifanib	3.33	27
11	dovitinib	3.09	21
12	jnj 7706621	3.09	21
13	at 9283	3.09	21
14	lestaurtinib	3.04	20
15	pf 03758309	3.00	19
16	ruboxistaurin	2.94	18
17	orantinib	2.89	17
18	r 406	2.83	16
19	k 252a	2.83	16
20	hesperadin	2.77	15
21	bms 345541	2.71	14
22	kw 2449	2.64	13
23	gsk 690693	2.64	13
24	ast 487	2.56	12
25	gsk 461364	2.40	10
26	azd 7762	2.30	9
27	su 014813	2.20	8
28	rebastinib	2.20	8
29	cyc 116	2.08	7
30	enzastaurin	2.08	7
31	amg 900	2.08	7
32	gsk 1059615	1.95	6
33	pf 03814735	1.79	5

About RPS6KA4 as a Drug Target

RPS6KA4 (Ribosomal protein S6 kinase alpha-4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 33 compounds with documented RPS6KA4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

RPS6KA4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.